We looked after a group of patients who had Minimally Invasive Surgery (MIS) for a kidney tumor and had Atypical Tumor Recurrence (ATR) involving port sites, intraperitoneal carcinomatosis, and nephrectomy bed/perinephric tumor implants. The purpose of this study was to look at the clinical characteristics, management, and oncologic outcomes of patients with localized Renal Cell Carcinoma (RCC) who developed ATR after curative-intent MIS for partial or radical nephrectomy. Patients with localized RCC who developed ATR after MIS for partial or radical nephrectomy at Memorial Sloan Kettering Cancer Center (New York, NY, USA) from 1999 to 2021 were included in the study cohort. Measurement of outcomes and statistical analysis: We gathered information on clinicopathologic features, treatments, time to ATR, and overall survival.
The 58 RCC patients had a median age of 61 years. 41 patients (71%) were male, 26 (45%) underwent robot-assisted surgery, and 39 (67%) had clear cell RCC. Twenty-nine patients (50%) had stage pT1 disease, with ten (17%) having positive surgical margins.
